Literature DB >> 22767587

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.

G Gullo, M Zuradelli, F Sclafani, A Santoro, J Crown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22767587     DOI： 10.1093/annonc/mds221

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

1.  Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?

Authors:  Amy Hsieh; Ken Pittman; William K Patterson; Amanda Townsend
Journal:  BMJ Case Rep       Date:  2015-06-03

2.  Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.

Authors:  Ines Vaz-Luis; Davinia Seah; Erin M Olson; Nikhil Wagle; Otto Metzger-Filho; Jessica Sohl; Georgia Litsas; Harold J Burstein; Ian E Krop; Eric P Winer; Nancy U Lin
Journal:  Clin Breast Cancer       Date:  2013-08       Impact factor: 3.225

3.  No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.

Authors:  Zachary Veitch; Domen Ribnikar; Derek Tilley; Patricia A Tang; Karen King; Philippe L Bedard; Sasha Lupichuk; David W Cescon
Journal:  Br J Cancer       Date:  2021-12-20       Impact factor: 9.075

4.  The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Authors:  Alexandra Canonici; Zulfiqar Qadir; Neil T Conlon; Denis M Collins; Neil A O'Brien; Naomi Walsh; Alex J Eustace; Norma O'Donovan; John Crown
Journal:  Invest New Drugs       Date:  2018-02-02       Impact factor: 3.850

Review 5.  Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission.

Authors:  R Haq; P Gulasingam
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

6.  Long-responders to anti-HER2 therapies: A case report and review of the literature.

Authors:  Luca Cantini; Mirco Pistelli; Agnese Savini; Lucia Bastianelli; Arianna Della Mora; Filippo Merloni; Michela Burattini; Rossana Berardi
Journal:  Mol Clin Oncol       Date:  2017-11-08

7.  PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Authors:  Martina Sj McDermott; Brigid C Browne; Neil T Conlon; Neil A O'Brien; Dennis J Slamon; Michael Henry; Paula Meleady; Martin Clynes; Paul Dowling; John Crown; Norma O'Donovan
Journal:  Mol Cancer       Date:  2014-06-24       Impact factor: 27.401

8.  The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Authors:  Angelo Gámez-Pozo; Ramón M Pérez Carrión; Luis Manso; Carmen Crespo; Cesar Mendiola; Rocío López-Vacas; Julia Berges-Soria; Isabel Álvarez López; Mireia Margeli; Juan L Bayo Calero; Xavier González Farre; Ana Santaballa; Eva M Ciruelos; Ruth Afonso; Juan Lao; Gustavo Catalán; José V Álvarez Gallego; José Miramón López; Francisco J Salvador Bofill; Manuel Ruiz Borrego; Enrique Espinosa; Juan A Fresno Vara; Pilar Zamora
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

9.  Harnessing the power of antibodies to fight bone metastasis.

Authors:  Zeru Tian; Ling Wu; Chenfei Yu; Yuda Chen; Zhan Xu; Igor Bado; Axel Loredo; Lushun Wang; Hai Wang; Kuan-Lin Wu; Weijie Zhang; Xiang H-F Zhang; Han Xiao
Journal:  Sci Adv       Date:  2021-06-23       Impact factor: 14.957

10.  When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.

Authors:  Ditte Marie Brix; Knut Kristoffer Bundgaard Clemmensen; Tuula Kallunki
Journal:  Cells       Date:  2014-01-27       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.